Objective:

To compare the efficacy and safety of a sustained-release fluocinolone acetonide implant with aflibercept in patients with retinal vascular disease.

Approach:

Key Findings:

• Fluocinolone implant showed fewer required injections compared to aflibercept.
• OCT thickness remained stable with fluocinolone, while it fluctuated with anti-VEGF therapy.
• Only 1.9% of participants required incisional glaucoma surgery.
• The majority of patients did not experience significant optic nerve damage despite concerns about IOP.

Interpretation:

Limitations:

• Statistical significance was not achieved for fewer injections in the fluocinolone arm.
• Small sample size for certain outcomes, such as incisional surgery.

Conclusion:

Fluocinolone acetonide demonstrates potential benefits in managing retinal vascular diseases with a favorable safety profile.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.